FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION.

CJC-1295 + Ipamorelin — Published Research

Reviewed by: Dr. James Porter, PhD| Last updated: abril 9, 2026|For laboratory reference only

← Back to CJC-1295 + Ipamorelin product page

Biblioteca de investigación

Published research on these compounds — for educational purposes only

GHRH and GHS Receptor Synergistic Signaling

The combination of GHRH analogs with growth hormone secretagogues (GHS) has been investigated for synergistic effects on somatotroph cells. GHRH activates the GHRH receptor (a class B GPCR) through cAMP/PKA signaling, while GHS peptides like ipamorelin activate the GHS-R1a receptor through phospholipase C/IP3/calcium pathways. Co-stimulation of both receptor systems on the same pituitary cell produces GH release that exceeds the sum of individual stimulations, as characterized in perfused rat pituitary models.

Bowers CY et al. “On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.” Endocrinology. 1984. PubMed

Ipamorelin Selectivity Profile

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide GH secretagogue characterized by high selectivity for GH release relative to other pituitary hormones. In swine pituitary cell culture models, ipamorelin stimulated GH release with an EC₅₀ of approximately 1.3 nM without significant effects on ACTH, cortisol, prolactin, or FSH/LH release at effective concentrations. This selectivity profile distinguishes it from earlier GHS compounds like GHRP-6 and hexarelin, which show broader hormonal stimulation.

Raun K et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998. PubMed

CJC-1295 (Mod GRF 1-29) Structure and Pharmacokinetics

CJC-1295 without DAC (also known as Modified GRF 1-29) is a tetra-substituted analog of GHRH(1-29) with modifications at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu). These substitutions confer resistance to DPP-IV and other proteolytic enzymes, extending the biological half-life from the approximately 7-minute native GHRH half-life to roughly 30 minutes. The peptide retains full agonist activity at the GHRH receptor with equivalent binding affinity to native GHRH(1-29).

Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” J Clin Endocrinol Metab. 2006. PubMed

Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.

Reviewed by

Dr. James Porter, PhD

Biochemist with a focus on peptide synthesis and structure-activity relationships. Reviews research summaries for scientific accuracy.

Editorial Review

Reviewed by Dr. Sarah Chen, PharmD y Dr. James Porter, PhD — Panda Peptides Research Team.

Last reviewed: April 2026.

This content summarizes published laboratory literature for research-reference purposes only. Products referenced by Panda Peptides are sold strictly for laboratory research use. This page is not intended as dosing, administration, treatment, or other human-use guidance.